Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00445510




Registration number
NCT00445510
Ethics application status
Date submitted
7/03/2007
Date registered
9/03/2007
Date last updated
4/06/2012

Titles & IDs
Public title
This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive Asthmatics Against an Antigen Challenge
Scientific title
A Double Blind, Placebo Controlled, Repeat Dose Study to Determine the Effect of GSK256066 87.5 Mcg to Protect Against AMP Challenge in the Lung in Mild Steroid-naive Asthmatics.
Secondary ID [1] 0 0
IPA106620
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Asthma 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GSK256066

Treatment: Drugs: GSK256066
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
AMP PC20: GSK256066 7 days of 87.5mcg vs placebo 2hrs post-dose on Day 7.
Timepoint [1] 0 0
Secondary outcome [1] 0 0
AMP PC20: GSK256066 7 days of 87.5mcg vs placebo 24hrs post-dose on Day 7. Exhaled Nitric Oxide: GSK256066 7 days of 87.5mcg vs placebo at Day 1; 1hr and 2hr, Day 7; 1hr, 2hr and 24hr.
Timepoint [1] 0 0

Eligibility
Key inclusion criteria
Inclusion: (All must Apply)

- Males and females aged 18 to 55 years inclusive.

- Documented history of bronchial asthma, first diagnosed at least 6 months prior to the
screening visit and currently being treated only with intermittent short-acting beta
-agonist therapy by inhalation.

- Pre-bronchodilator FEV1 >75% of predicted at screening.

- Documented sensitivity to AMP with a provocative concentration of AMP resulting in a
20% fall in FEV1 (PC20 AMP) of <80 mg/ml at the screening visit.

- Demonstrate stable bronchoconstriction in response to inhaled AMP at the run-in visit.
'Stable bronchoconstriction' is a term to define a population of asthmatics who have a
repeatable and reproducible response to a challenge agent that induces
bronchoconstriction. The run-in PC20 needs to be within 1.25DD of the screening PC20.

- Non-smoking status as verified by urinary cotinine levels below 300 ng/mL cotinine at
the screening visit. This can include ex-smokers who have given up smoking for >6
months and have less than a 5 pack-year smoking history.

- Able and willing to give written informed consent to take part in the study.

- Available to complete all study measurements.
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion:

- Pregnant or nursing females.

- Past or present disease, which as judged by the investigator, may affect the outcome
of this study.

- Subject has known history of hypertension or is hypertensive at screening.

- Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the
first dose of study medication.

- History of life-threatening asthma, defined as an asthma episode that required
intubation and/or was associated with hypercapnoea, respiratory arrest and/or hypoxic
seizures.

- Unable to abstain from prescription medication, other than short acting inhaled
beta-agonists and paracetamol for the treatment of minor ailments eg headache from 48h
before the first dose until the follow-up visit.

- The subject has participated in a clinical trial during the previous 3 months.

- History of blood donation (450 mL) within 2 months of starting the clinical study.

- The subject regularly drinks more than 28 units of alcohol in a week if male, or 21
units per week if female.

- The subject has tested positive for hepatitis C antibody or hepatitis B surface
antigen or HIV antibodies.

- The subject has positive drugs of abuse test.

- Subjects weighing less than 50kg are to be excluded from participating in the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2006
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Wellington

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This will be a single centre, randomised, double-blind, placebo-controlled, 2-period
crossover study to investigate the effect of treatment with repeat inhaled doses of GSK256066
on bronchial hyper-reactivity to adenosine monophosphate.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00445510
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00445510